Q3 EPS Estimate for Mind Medicine (MindMed) Cut by Analyst

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Stock analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a note issued to investors on Monday, August 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.51) per share for the quarter, down from their prior forecast of ($0.36). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)’s Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.04) EPS and FY2027 earnings at ($1.48) EPS.

Several other brokerages have also issued reports on MNMD. Oppenheimer assumed coverage on Mind Medicine (MindMed) in a research report on Monday. They set an “outperform” rating and a $25.00 target price for the company. Cantor Fitzgerald raised Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Tuesday, May 13th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a report on Friday, August 1st. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Mind Medicine (MindMed) currently has an average rating of “Buy” and a consensus target price of $24.71.

Mind Medicine (MindMed) Stock Up 2.6%

Shares of NASDAQ MNMD opened at $9.89 on Wednesday. Mind Medicine has a 12 month low of $4.70 and a 12 month high of $10.44. The company has a market cap of $747.19 million, a price-to-earnings ratio of -6.46 and a beta of 2.49. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average price of $7.97 and a two-hundred day moving average price of $7.17.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.12).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MNMD. Teacher Retirement System of Texas lifted its holdings in Mind Medicine (MindMed) by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in Mind Medicine (MindMed) by 6.3% in the 2nd quarter. Palumbo Wealth Management LLC now owns 24,043 shares of the company’s stock worth $156,000 after buying an additional 1,415 shares during the period. Corebridge Financial Inc. grew its stake in Mind Medicine (MindMed) by 4.1% in the 4th quarter. Corebridge Financial Inc. now owns 40,064 shares of the company’s stock valued at $279,000 after buying an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Mind Medicine (MindMed) by 6.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,867 shares of the company’s stock valued at $169,000 after acquiring an additional 1,669 shares during the period. Finally, CWM LLC lifted its position in shares of Mind Medicine (MindMed) by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after acquiring an additional 1,796 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Insider Transactions at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 26,491 shares of the business’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total transaction of $180,138.80. Following the completion of the sale, the chief executive officer directly owned 830,065 shares of the company’s stock, valued at $5,644,442. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Sullivan sold 11,491 shares of the firm’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total transaction of $78,138.80. Following the completion of the transaction, the insider directly owned 305,130 shares in the company, valued at approximately $2,074,884. The trade was a 3.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,830 shares of company stock valued at $311,644 over the last ninety days. 2.45% of the stock is owned by company insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.